

about 0.5-3.5 % (w/w) lecithin and the balance stearin, wherein said GnRH agonist is other than deslorelin.

18. (New). A formulation according to claim 17, comprising about 5-10 % (w/w) of the GnRH agonist (on an active basis), about 0.5-1.5 % (w/w) lecithin and about 89-94 % (w/w) stearin.

19. (New). A formulation according to claim 18, comprising about 5 % (w/w) of the GnRH agonist (on an active basis), 1 % (w/w) lecithin and 94 % (w/w) stearin.

20. (New). A formulation according to claim 18, comprising about 5 % (w/w) of the GnRH agonist (on an active basis), 2 % (w/w) lecithin and 93 % (w/w) stearin.

21. (New). A formulation according to claim 17, wherein the GnRH agonist is a peptide.

22. (New). A formulation according to claim 17, wherein the lecithin and stearin are in a non-crystalline form.

23. (New). A method of treating a disease or condition in an animal for which suppression of sex hormone levels is beneficial, the method comprising administering

to the animal an effective amount of the formulation of claim 17 to ameliorate said disease or condition.

24. (New). A method according to claim 23, wherein the disease or condition is selected from the group consisting of prostate cancer, ovarian and breast cancer, endometriosis, myoma, pre-menstrual tension, uterine fibroids, hirsutism, cyclic auditory dysfunction, porphyria and precocious puberty.

25. (New). A method according to claim 23, wherein the lecithin and stearin are in a non-crystalline form.

AH
26. (New). A method of preventing reproductive function from functioning in an animal, the method comprising administering to the animal the formulation of claim 17.

27. (New). A method according to claim 25, wherein the lecithin and stearin are in a non-crystalline form.

28. (New). A method of treating benign prostatic hyperplasia in an animal, the method comprising administering to the animal the formulation of claim 17 whereby treating the benign prostatic hyperplasia.

TRIGG et al
Serial No. Unassigned

29. (New). A method according to claim 28, wherein the animal being treated is a dog.

AH

30. (New). A method according to claim 28, wherein the lecithin and stearin are in a non-crystalline form.

SEARCHED INDEXED SERIALIZED FILED